Development of an AlphaScreen Assay for Epigenetic Peptide-Protein Interactions: A Target-Family Approach to the Discovery of MBT Antagonists
Tim Wigle, Researcher, University of North Carolina, speaking at Probe Discovery 2009
T-Cell Monitoring of Clinical Samples – Precise and Robust Assays based on DNA Methylation Markers
Ulrich Hoffmueller, Chief Business Officer, Epiontis GmbH, speaking at European Biomarkers Summit 2009
Experiences in Fragment-Based Lead Discovery
Ben Davis, Principal Scientist, NMR, Vernalis, speaking at Screening Europe 2010
Excitement Over Automated Electrophysiology: Heat Activation of TRPV1 and Action Potentials of Stem Cell Derived Cardiomyocytes
Rodolfo Haedo, Nanion Technologies, General Manager, speaking at Ion Channel Targets 2010.
Quartz and Glass Nanopore Membranes for Ultra-low Noise Measurement of Ion Channel Activity
Prithwish Pal, Electronic Biosciences, Research Scientist, speaking at Ion Channel Targets 2010.
Developing Novel Chloride-Channel Inhibitors
Merritt Maduke, Stanford School of Medicine, Associate Professor, speaking at Ion Channel Targets 2010.
FBS by Biochemical Assays – Does This Make Sense?
Julian Woelcke, Associate Director, Novartis Pharma AG, speaking at Screening Europe 2010.
Development of an AlphsScreen HTS Assay for Low Affinity Epigenetic Peptide-Protein Interactions
Tim Wigle, Postdoc, University of North Carolina, speaking at Screening Europe 2010.
Kinome Activity Profiling: A New Approach for Target Discovery and Response Prediction
Rinie van Beuningen, Vice President Business Development, PamGene International B.V., speaking at Screening Europe 2010.